[Correspondence] Bioresorbable polymer drug-eluting stents

I read with great interest the results of the BIOFLOW V trial (Oct 21, 2017, p 1843).1 David Kandzari and colleagues should be congratulated on such an important study. The authors concluded that an ultrathin bioresorbable polymer drug-eluting stent (BRP-DES) outperformed a durable polymer-eluting stent (DP-DES) because the proportion of patients who had target-vessel myocardial infarctions at 12 months was lower in the BRP-DES group than in the DP-DES group. However, the proportion of patients who had myocardial infarction at 12 months was substantially higher in the DP-DES group than in previous trials comparing a BRP-DES with a DP-DES (table).
Source: LANCET - Category: General Medicine Authors: Tags: Correspondence Source Type: research